NextCure And Avere Therapeutics Announce Merger To Advance Oral IL-23 Therapy; Stock Up
NextCure (NXTC) agreed to an all-stock merger with private Avere Therapeutics to form Avere Therapeutics, expected to close in 2H 2026. The combined firm will trade on Nasdaq as AVRX. Avere’s lead oral IL-23 antagonist AVR-001 is in Phase 1b. Financing includes a $320M private placement with $251M convertible notes, aimed to fund psoriasis Phase 2b and Phase 3 start, plus ulcerative colitis Phase 2b.
How this was made
The 30-second read
Why it matters
The deal combines Avere’s oral peptide IL-23 pipeline with NextCure’s public-market infrastructure and is backed by a $320M private placement, including $251M convertible notes exchanged for common stock at closing. The combined company is expected to trade on Nasdaq as AVRX in 2H 2026, with specified leadership and planned clinical milestones.
Market read
Definitive biotech M&A plus a large concurrent financing is a direct catalyst for deal-probability pricing, volatility, and potential spread trades in NXTC and the post-close AVRX vehicle.
What to watch
Key trading risks are merger closing conditions, potential dilution from the convertible-note exchange, and the clinical de-risking timeline (Phase 2b readout in psoriasis and Phase 3 initiation) that may not align with near-term investor expectations.
Background
NextCure (NXTC) announced a definitive all-stock merger with privately held Avere Therapeutics, focused on oral IL-23 receptor antagonist therapy (AVR-001).
Ticker impact
NextCure entered a definitive all-stock merger with Avere, with closing expected in 2H 2026 and a new combined-company Nasdaq ticker.
Likely continued volatility and upside bias pre-close, with risk tied to deal execution and financing/closing conditions.
The article discloses a definitive merger agreement, expected closing timing, and a concurrent $320M private placement, all of which typically drive immediate repricing and deal-spread dynamics.
Market effects
Highlights continued investor appetite for oral IL-23 programs and deal financing structures in inflammatory-disease biotech.
Primarily US-listed biotech sentiment via Nasdaq listing mechanics and deal probability pricing.
Involves Hansoh Pharmaceutical Group as a financing participant, signaling cross-border capital support for late-stage inflammatory assets.
Counterpoint
The stock’s pre-market surge may over-discount deal certainty; without disclosed exchange ratio and detailed closing conditions, downside can emerge quickly if regulatory or financing hurdles appear.
Key entities
- public_companyNextCure, Inc.
Entered a definitive all-stock merger agreement with Avere Therapeutics; NXTC is the current trading vehicle.
- private_companyAvere Therapeutics, Inc.
Biotech focused on oral IL-23 therapies; lead program AVR-001.
- investorFairmount
Led the concurrent $320M private placement financing.
- investorHansoh Pharmaceutical Group Co., Ltd.
Participated in the concurrent $320M private placement financing.
- executiveAndrew Cheng, MD, PhD
Named CEO, President, and Chairman of the combined company.
